Get to know our clinical trials
Multicenter, randomized, double-blind, placebo-controlled, Phase III clinical trial to investigate the efficacy, safety and tolerability of Ritlecitinib in adult participants with non-segmental vitiligo.
THE AIM OF THIS STUDY IS TO FIND OUT WHETHER RITLECITINIB IS EFFECTIVE IN THE TREATMENT OF VITILIGO AND WHETHER IT IS SAFE FOR USE IN HUMANS.
Status
In recruitment
headquarters
Madrid
Technical Summary
- MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NON-SEGMENTAL VITILIGO.
- Code EudraCT: 2022-502518-98-00
- Protocol number: B7981080
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.